In a recently published report, Lopinavir and Ritonavir Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.
U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Lopinavir and Ritonavir Market products.
“Final Report will add the analysis of the impact of COVID-19 on this industry.”
Click Here to Download Sample Report >> https://www.kennethresearch.com/sample-request-10324780
Moreover, increasing expenditure on healthcare, backed by the need amongst individuals for quality healthcare services, is also anticipated to contribute to the market growth. According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 9.08% in 2001 to 9.84% in 2018. Additionally, the current health expenditure per capita (current US$) increased from USD 492.99 in 2001 to USD 1110.84 in 2018.
Global Gastric Cancer Drugs Market is valued approximately USD 3.0 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 15.5% over the forecast period 2020-2026. Gastric cancer, also known as stomach cancer, is characterized by an intensification of cancerous cells within the lining of the stomach. This type of cancer is usually complex to identify because most people normally do not show symptoms at the earlier stages. While gastric cancer is quite rare as compared to other forms of cancer. There are some other factors of gastric cancer that include certain diseases and conditions such as lymphoma, tumors in other parts of the digestive system, stomach polyps and many more. For these reasons, a number of chemo drugs are used to treat gastric cancer, including: 5-FU (fluorouracil), frequently given along with leucovorin (folinic acid), Capecitabine (Xeloda), Carboplatin, and many more. High incidences of gastric cancer among people owing to unhealthy diet, increasing number of obesity cases and growing elderly population are the few factors responsible for high CAGR of the market over the forecast period.
For instance, the National Cancer Institute (NCI) estimated that around 28,000 new cases of stomach cancer in 2017. Also, NCI estimates that stomach cancer is about 1.7 percent of new cancer cases in the United States. Similarly, as per the GLOBOCAN 2018, the number of prevalence cases of stomach cancer in Asia was around 769,728 and is projected to grow to almost 947,186 by 2025. Although gastric cancer therapies can increase the chances of survival for patients living with gastric cancer. This, in turn, is expected to accelerate the demand of Gastric Cancer Drugs around the world. Amidst the COVID-19 outbreak across the world, the pharma industry is more concerned on the development of COVID-19 vaccine, thus, R&D efforts for gastric cancer drugs is substantially decline. Though, the demand for gastric cancer drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at significant rate in the upcoming years. However, high cost of cancer therapy and stringent regulations and policies for approval of the drugs are some other factor limiting the market growth over the forecast period of 2020-2026.
The regional analysis of global Gastric Cancer Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia-Pacific is the leading/significant region across the world in terms of market share owing to rising number of gastric cancer cases, introduction of novel therapies for metastatic gastric cancer, and the presence of larger consumer base seeking treatment, particularly in China, India and Japan. Whereas, North America is anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing R&D efforts by pharmaceuticals for gastric cancer drugs and supportive government policies in the region.
Major market player included in this report are:
Amgen
AROG Pharmaceuticals
Ipsen Biopharmaceuticals
Array Biopharma
Taiho Oncology
AstraZeneca
ARIAD Pharmaceuticals
Eli Lilly
Galena Biopharma
ASLAN Pharmaceuticals
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Route of Administration:
Oral
Parenteral
By Lines of Chemotherapy:
First-line Chemotherapy
Second-line Chemotherapy
By Molecule Type:
Small Molecule
Biologics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026
Target Audience of the Global Gastric Cancer Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Request For The Sample Report Here: https://www.kennethresearch.com/sample-request-10324780
TABLE OF CONTENTS
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Billion)
1.2.1. Gastric Cancer Drugs Market, by Region, 2018-2026 (USD Billion)
1.2.2. Gastric Cancer Drugs Market, by Route of Administration, 2018-2026 (USD Billion)
1.2.3. Gastric Cancer Drugs Market, by Lines of Chemotherapy, 2018-2026 (USD Billion)
1.2.4. Gastric Cancer Drugs Market, by Molecule Type, 2018-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Gastric Cancer Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Gastric Cancer Drugs Market Dynamics
3.1. Gastric Cancer Drugs Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Gastric Cancer Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Gastric Cancer Drugs Market, by Route of Administration
5.1. Market Snapshot
5.2. Global Gastric Cancer Drugs Market by Route of Administration, Performance – Potential Analysis
5.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Route of Administration 2016-2026 (USD Billion)
5.4. Gastric Cancer Drugs Market, Sub Segment Analysis
5.4.1. Oral
5.4.2. Parenteral
Chapter 6. Global Gastric Cancer Drugs Market, by Lines of Chemotherapy
6.1. Market Snapshot
6.2. Global Gastric Cancer Drugs Market by Lines of Chemotherapy, Performance – Potential Analysis
6.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Lines of Chemotherapy 2016-2026 (USD Billion)
6.4. Gastric Cancer Drugs Market, Sub Segment Analysis
6.4.1. First-line Chemotherapy
6.4.2. Second-line Chemotherapy
About Kenneth Research:
Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products’ demand, growth and opportunities for new and existing players.
Contact Us
Kenneth Research
Email: [email protected]
Phone: +1 313 462 0609
N95 Grade Medical Protective Masks Market
Diagnostic Imaging Market
Vaccine and Drugs Market
Modular Healthcare Facilities Market
Patient Temperature Management Devices Market
